Skip to main content
. 2022 Mar 14;11(3):551. doi: 10.3390/antiox11030551

Table 3.

Levels of lipid peroxidation compounds in plasma samples from each participants group.

Variable
(nmol·L−1)		 Healthy
(n = 80)
Median
(1st, 3rd Quartile)		 MCI-AD
(n = 106)
Median
(1st, 3rd Quartile)		 MD-AD
(n = 70)
Median
(1st, 3rd Quartile)		 AD-AD
(n = 11)
Median
(1st, 3rd Quartile)		 Non-AD
(n = 20)
Median
(1st, 3rd Quartile)		 p Value
(Kruskal-Wallis Test)
PGs a PGE2 0.27 (0.05–0.45) 0.07 (0–0.35) 0.12 (0.04–0.50) 0.10 (0–0.20) 0.10 (0.07–0.16) 0.03 *
PGF2α 0.55 (0.28–0.86) 0.60 (0.10–0.85) 0.63 (0.26–1.13) 0.60 (0.30–0.80) 0.88 (0.53–1.38) 0.058 ^
15-E2t-IsoP 0.78 (0.27–1.56) 0.31 (0.09–1.01) 0.30 (0.07–1.08) 0.25 (0–0.67) 0.13 (0.05–0.29) <0.01 *
15-F2t-IsoP 0.03 (0.01–0.06) 0.02 (0–0.05) 0.03 (0–0.21) 0.02 (0–0.03) 0 (0–0.57) 0.08
IsoPs a 15(R)-15-F2t-IsoP 0.31 (0.20–0.59) 0.30 (0.16–0.53) 0.35 (0.20–0.58) 0.25 (0.06–0.45) 0.48 (0.21–0.75) 0.21
2,3-dinor-15-epi-15-F2t-IsoP 0 (0–0.02) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0.58
15-keto-15-E2t-IsoP 0.33 (0–0.92) 0 (0–0.17) 0.01 (0–0.25) 0 (0–0.32) 0.05 (0–0.38) <0.01 *
15-keto-15-F2t-IsoP 0.37 (0.17–0.67) 0.25 (0.07–0.40) 0.33 (0.15–0.56) 0.27 (0.07–0.40) 0.47 (0.30–0.78) <0.01 *
5-F2t-IsoP 1.38 (0.88–2.62) 0.98 (0.33–1.69) 1.25 (0.65–2.00) 0.65 (0.35–1.45) 1.98 (1.08–2.55) <0.01 *
Total IsoPs 0.72 (0.31–1.39) 0.39 (0.26–0.67) 0.45 (0.30–0.68) 0.27 (0.22–0.37) 0.62 (0.44–0.79) <0.01 *
IsoFs a Total IsoFs 0.33 (0.08–0.46) 0.14 (0.08–0.32) 0.19 (0.09–0.36) 0.08 (0.05–0.14) 0.23 (0.19–0.40) <0.01 *
NeuroPs b 4(RS)-4-F4t-NeuroP 1.37 (0.95–3.68) 1.10 (0–1.50) 1.08 (0.58–1.40) 0.97 (0–1.27) 1.03 (0.61–1.46) <0.01 *
10-epi-10-F4t-NeuroP 0.15 (0.06–0.22) 0.13 (0.01–0.22) 0.20 (0.05–0.32) 0.11 (0.07–0.20) 0.32 (0.25–0.41) <0.01 *
14(RS)-14-F4t-NeuroP 1.08 (0.13–1.89) 0.53 (0–1.58) 0.88 (0.25–1.30) 0.15 (0–0.42) 0.91 (0.60–1.43) 0.01 *
Total NeuroPs 0.05 (0–0.56) 0 (0–0.11) 0 (0–0.05) 0 (0–0.38) 0.01 (0–0.06) <0.01 *
NeuroFs b Total NeuroFs 0.16 (0.06–0.32) 0.15 (0.05–0.33) 0.12 (0.05–0.25) 0.09 (0–0.11) 0.08 (0.04–0.15) 0.02 *
Dihomo-IsoPs c 1a,1b-dihomo-PGF2α 0 (0–3.34) 0 (0–0) 0 (0–1.03) 0 (0–0) 1.18 (0–1.40) <0.01 *
Ent-7(RS)-7-F2t-dihomo-IsoP 0.03 (0–0.17) 0.10 (0–0.22) 0.15 (0.10–0.22) 0.15 (0.05–0.22) 0.12 (0.10–0.19) <0.01 *
17-F2t-dihomo-IsoP 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0.10
17-epi-17-F2t-dihomo-IsoP 0 (0–0) 0 (0–0.02) 0 (0–0.02) 0 (0–0.02) 0 (0–0) 0.054 ^
Dihomo-IsoFs c 17(RS)-10-epi-SC-Δ15-11-dihomo-IsoF 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0.07
7(RS)-ST-Δ8-11-dihomo-IsoF 0 (0–0.22) 0 (0–0.17) 0.02 (0–0.10) 0.05 (0.02–0.12) 0 (0–0.09) 0.52

a = Lipid peroxidation compounds derived from the oxidation of AA; b = Lipids derived from the oxidation of DHA; c = Lipids derived from the oxidation of AdA; * p value < 0.05; ^ p value near to 0.05.